Table 3 Correlation of CDK4 pathway aberrations to clinicopathologic features of mucosal melanoma
Clinicopathologic factor | CDK4 aberration | CCND1 aberration | |||||
|---|---|---|---|---|---|---|---|
Gain | Normal | P value | Gain | Loss | Normal | P value | |
Age (year) | Â | Â | 0.552 | Â | Â | Â | 0.853 |
Median (range) | 56.5 ± 11.6 | 54.9 ± 11.3 |  | 56.4 ± 11.3 | 55.3 ± 11.6 | 55.4 ± 11.6 |  |
Gender n (%) | Â | Â | 0.409 | Â | Â | Â | 0.413 |
 Male | 41 (41.0) | 39 (35.5) |  | 20 (33.9) | 18 (47.4) | 45 (38.8) |  |
 Female | 59 (59.0) | 71 (64.5) |  | 39 (66.1) | 20 (52.6) | 71 (61.2) |  |
Ulceration n (%) | Â | Â | 0.555 | Â | Â | Â | 0.769 |
 Yes | 52 (52.0) | 49 (44.5) |  | 25 (42.4) | 20 (52.6) | 58 (50.0) |  |
 No | 20 (20.0) | 26 (23.6) |  | 14 (23.7) | 9 (23.7) | 23 (19.8) |  |
 NA | 28 (28.0) | 35 (31.8) |  | 20 (33.9) | 9 (23.7) | 35 (30.2) |  |
Depth of invasion | Â | Â | 0.981 | Â | Â | Â | 0.853 |
 T1 ≤ 1 mm | 13 (13.0) | 16 (14.5) |  | 10 (16.9) | 4 (10.5) | 15 (12.9) |  |
 T2 1–2 mm | 21 (21.0) | 24 (21.8) |  | 10 (16.9) | 11 (28.9) | 25 (21.6) |  |
 T3 2–4 mm | 18 (18.0) | 20 (18.2) |  | 10 (16.9) | 6 (15.8) | 22 (19.0) |  |
 T4 > 4 mm | 48 (48.0) | 50 (45.5) |  | 29 (49.2) | 17 (44.7) | 54 (46.6) |  |
Anatomic site n (%) | Â | Â | 0.153 | Â | Â | Â | 0.885 |
 Head and neck | 51 (51.0) | 41 (37.3) |  | 27 (45.8) | 15 (39.5) | 52 (44.8) |  |
 Oesophagus | 8 (8.0) | 11 (10.0) |  | 3 (5.1) | 5 (13.2) | 11 (9.5) |  |
 Anorectum | 21 (21.0) | 23 (20.9) |  | 13 (22.0) | 9 (23.7) | 23 (19.8) |  |
 Genitourinary | 20 (20.0) | 35 (31.8) |  | 16 (27.1) | 9 (23.7) | 30 (25.9) |  |
Stages n (%) | Â | Â | 0.004 | Â | Â | Â | 0.239 |
 I | 5 (5.0) | 1 (0.9) |  | 0 (0.0) | 1 (2.6) | 5 (4.3) |  |
 II | 46 (46.0) | 67 (60.9) |  | 30 (50.8) | 26 (68.4) | 58 (50.0) |  |
 III | 38 (38.0) | 22 (20.0) |  | 18 (30.5) | 9 (23.7) | 34 (29.3) |  |
 IV | 11 (11.0) | 20 (18.0) |  | 11 (18.6) | 2 (5.3) | 19 (16.4) |  |
Survival (months) | Â | Â | 0.054 | Â | Â | Â | 0.702 |
 Median (95% CI) | 45.0 (39.3, 50.7) | 41.2 (35.4, 47.0) |  | 43 (40.2, 45.8) | 47.4 (38.9, 55.9) | 45.0 (40.0, 50.0) |  |
 Median follow-up time (95% CI) | 38.1 (26.0, 50.2) | 37.0 (25.5, 48.5) | 0.322 | 44.5 (27.4, 61.6) | 39.5 (22.2, 56.8) | 31.0 (18.3, 43.7) | 0.453 |
Clinicopathologic factor | P16INK4a aberration | Overall aberration (≥ 1 CNV) | ||||
|---|---|---|---|---|---|---|
Loss | Normal | P value | Yes | No | P value | |
Age (year) | Â | Â | 0.733 | Â | Â | 0.581 |
Median (range) | 55.4 ± 11.5 | 56.2 ± 11.4 |  | 55.5 ± 11.4 | 56.3 ± 12.0 |  |
Gender n (%) | Â | Â | 0.903 | Â | Â | 0.771 |
 Male | 48 (39.0) | 34 (38.2) |  | 67 (38.5) | 16 (41.0) |  |
 Female | 75 (61.0) | 55 (61.8) |  | 107 (61.5) | 23 (59.0) |  |
Ulceration n (%) | Â | Â | 0.014 | Â | Â | 0.189 |
 Yes | 52 (42.3) | 51 (57.3) |  | 81 (46.6) | 22 (56.4) |  |
 No | 25 (20.3) | 21 (23.6) |  | 36 (20.7) | 10 (25.6) |  |
 NA | 46 (37.4) | 17 (119.1) |  | 36 (20.7) | 7 (17.9) |  |
Depth of invasion | Â | Â | 0.053 | Â | Â | 0.348 |
 T1 ≤ 1 mm | 20 (16.3) | 9 (10.1) |  | 26 (14.9) | 3 (7.7) |  |
 T2 1–2 mm | 33 (26.8) | 13 (14.6) |  | 40 (23.0) | 6 (15.4) |  |
 T3 2–4 mm | 19 (15.4) | 19 (21.3) |  | 29 (16.7) | 9 (23.1) |  |
 T4 > 4 mm | 51 (41.5) | 48 (53.9) |  | 79 (45.4) | 21 (53.8) |  |
Anatomic site n (%) | Â | Â | 0.379 | Â | Â | 0.691 |
 Head and neck | 55 (44.7) | 39 (43.8) |  | 79 (45.4) | 15 (38.5) |  |
 Oesophagus | 14 (11.4) | 5 (5.6) |  | 16 (9.2) | 3 (7.7) |  |
 Anorectum | 22 (17.9) | 22 (24.7) |  | 34 (19.5) | 11 (28.2) |  |
 Genitourinary | 32 (26.0) | 23 (25.8) |  | 45 (25.9) | 10 (25.6) |  |
Stages n (%) | Â | Â | 0.515 | Â | Â | Â |
 I | 4 (3.3) | 2 (2.2) |  | 5 (2.9) | 1 (2.6) | 0.059 |
 II | 65 (52.8) | 49 (55.1) |  | 90 (51.7) | 24 (61.5) |  |
 III | 39 (31.7) | 22 (24.7) |  | 56 (32.2) | 5 (12.8) |  |
 IV | 15 (12.2) | 16 (18.0) |  | 23 (13.2) | 9 (23.1) |  |
Survival (months) | Â | Â | 0.528 | Â | Â | 0.169 |
 Median (95% CI) | 43.6 (40.0, 47.2) | 43.6 (32.3, 54.9) |  | 44.0 (40.4, 47.6) | 43.6 (18.6, 68.6) |  |
 Median follow-up time (95% CI) | 39.7 (29.7, 49.7) | 33.7 (22.3, 45.1) | 0.137 | 38.1 (31.7, 44.5) | 21.9 (17.8, 26.0) | 0.206 |
Clinicopathologic factor | CDK4 gain + CCND1 gain | CDK4 gain + P16INK4a loss | ||||
|---|---|---|---|---|---|---|
Positive | Negative | P value | Positive | Negative | P value | |
Age (year) | Â | Â | 0.866 | Â | Â | 0.722 |
Median (range) | 57.6 ± 11.1 | 55.4 ± 11.5 |  | 56.2 ± 11.1 | 55.5 ± 11.6 |  |
Gender n (%) | Â | Â | 0.817 | Â | Â | 0.382 |
 Male | 12 (40.0) | 68 (37.8) |  | 28 (42.4) | 52 (36.1) |  |
 Female | 18 (60.0) | 112 (62.2) |  | 38 (57.6) | 92 (63.9) |  |
Ulceration n (%) | Â | Â | 0.690 | Â | Â | 0.971 |
 Yes | 13 (43.3) | 88 (48.9) |  | 31 (47.0) | 70 (48.6) |  |
 No | 6 (20.0) | 40 (22.2) |  | 15 (22.7) | 31 (21.5) |  |
 NA | 11 (36.7) | 52 (28.9) |  | 20 (30.3) | 43 (29.9) |  |
Depth of invasion | Â | Â | 0.767 | Â | Â | 0.527 |
 T1 ≤ 1 mm | 3 (10.0) | 26 (14.4) |  | 8 (12.1) | 21 (14.6) |  |
 T2 1–2 mm | 5 (16.7) | 40 (22.2) |  | 18 (27.3) | 27 (18.8) |  |
 T3 2–4 mm | 6 (20.0) | 32 (17.8) |  | 10 (15.2) | 28 (19.4) |  |
 T4 > 4 mm | 16 (53.3) | 82 (45.6) |  | 30 (45.5) | 68 (47.2) |  |
Anatomic site n (%) | Â | Â | 0.160 | Â | Â | 0.935 |
 Head and neck | 16 (53.3) | 76 (42.2) |  | 31 (47.0) | 61 (42.4) |  |
 Oesophagus | 3 (10.0) | 16 (8.9) |  | 6 (9.1) | 13 (9.0) |  |
 Anorectum | 8 (26.7) | 36 (20.0) |  | 13 (19.7) | 31 (21.5) |  |
 Genitourinary | 3 (10.0) | 52 (28.9) |  | 16 (24.2) | 39 (27.1) |  |
Stages n (%) | Â | Â | 0.213 | Â | Â | 0.088 |
 I | 0 (0.0) | 6 (3.3) |  | 4 (6.1) | 2 (1.4) |  |
 II | 12 (40.0) | 101 (56.1) |  | 32 (48.5) | 81 (56.2) |  |
 III | 12 (40.0) | 48 (26.7) |  | 23 (34.8) | 37 (25.7) |  |
 IV | 6 (20.0) | 25 (13.9) |  | 7 (10.6) | 24 (16.7) |  |
Survival (months) | Â | Â | 0.757 | Â | Â | 0.174 |
 Median (95% CI) | 44.0 (41.4, 46.6) | 43.6 (39.3, 47.9) |  | 44.0 (41.4, 46.6) | 43.0 (37.6, 48.4) |  |
 Median follow-up time (95% CI) | 54.0 (29.2, 78.8) | 37.0 (30.0, 44.0) | 0.636 | 38.1 (25.9, 50.3) | 37.0 (29.1, 44.9) | 0.153 |
Clinicopathologic factor | P16INK4a loss + CCND1 gain | CDK4 gain + P16INK4a loss + CCND1 gain | ||||
|---|---|---|---|---|---|---|
Positive | Negative | P value | Positive | Negative | P value | |
Age (year) | Â | Â | 0.531 | Â | Â | 0.807 |
Median (range) | 58.1 ± 12.5 | 55.3 ± 11.2 |  | 59.2 ± 12.8 | 55.3 ± 11.4 |  |
Gender n (%) | Â | Â | 0.927 | Â | Â | 0.476 |
 Male | 13 (39.4) | 69 (38.5) |  | 8 (47.1) | 75 (38.3) |  |
 Female | 20 (60.6) | 110 (61.5) |  | 9 (52.9) | 121 (61.7) |  |
Ulceration n (%) | Â | Â | 0.220 | Â | Â | 0.857 |
 Yes | 13 (39.4) | 90 (50.3) |  | 8 (47.1) | 95 (48.5) |  |
 No | 6 (18.2) | 40 (22.3) |  | 3 (17.6) | 43 (21.9) |  |
 NA | 14 (42.4) | 49 (27.4) |  | 6 (35.3) | 58 (29.6) |  |
Depth of invasion | Â | Â | 0.584 | Â | Â | 0.682 |
 T1 ≤ 1 mm | 7 (21.2) | 22 (12.3) |  | 1 (5.9) | 28 (14.3) |  |
 T2 1–2 mm | 7 (21.1) | 39 (21.8) |  | 3 (17.6) | 43 (21.9) |  |
 T3 2–4 mm | 5 (15.2) | 33 (18.4) |  | 3 (17.6) | 35 (17.9) |  |
 T4 > 4 mm | 14 (42.4) | 85 (47.5) |  | 10 (58.8) | 90 (45.9) |  |
Anatomic site n (%) | Â | Â | 0.404 | Â | Â | 0.497 |
 Head and neck | 18 (54.5) | 76 (42.5) |  | 9 (52.9.6) | 85 (43.4) |  |
 Oesophagus | 1 (3.0) | 18 (10.0) |  | 1 (5.9) | 18 (9.2) |  |
 Anorectum | 6 (18.2) | 38 (21.1) |  | 5 (29.4) | 40 (20.4) |  |
 Genitourinary | 8 (24.2) | 47 (26.1) |  | 2 (11.8) | 53 (27.0) |  |
Stages n (%) | Â | Â | 0.383 | Â | Â | 0.268 |
 I | 0 (0.0) | 6 (3.4) |  | 0 (0.0) | 6 (3.1) |  |
 II | 16 (48.5) | 98 (54.7) |  | 6 (35.3) | 108 (55.1) |  |
 III | 13 (39.4) | 48 (26.8) |  | 8 (47.1) | 53 (27.0) |  |
 IV | 4 (12.1) | 27 (15.1) |  | 3 (17.6) | 29 (14.8) |  |
Survival (months) | Â | Â | 0.287 | Â | Â | 0.145 |
 Median (95% CI) | 42 (35.0, 49.0) | 45.5 (40.8, 50.2) |  | 42 (33.5, 50.5) | 45 (40.5, 49.4) |  |
 Median follow-up time (95% CI) | 55.5 (20.3, 90.7) | 35.0 (27.6, 42.4) | 0.102 | 38.1 (25.9, 50.3) | 37.0 (29.1, 44.9) | 0.153 |